Showing results (181-190 of 880) with videos related to

Sort By:
Pageof 88
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 7, 2016
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysisKevin Quach, Lyubov Lvtvyn, Colin Baigent, et al.
Internal Medicine Journal|August 22, 2018
Effectiveness of corticosteroid compared with non-corticosteroid therapy for the treatment of drug-induced acute interstitial nephritis: a systematic reviewLena R Quinto, Louisa Sukkar, Martin Gallagher
Diabetes, Obesity & Metabolism|January 31, 2019
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysisTadashi Toyama, Brendon L Neuen, Min Jun, et al.
Nephrology (Carlton, Vic.)|December 23, 2014
Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis': the ACTIVE Dialysis StudyMeg J Jardine, L I Zuo, Nicholas A Gray, et al.
Kidney International Reports|May 14, 2023
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN StudyDana V Rizk, Brad H Rovin, Hong Zhang, et al.
Journal of the American Heart Association|December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS TrialTaha Sen, Jingwei Li, Brendon L Neuen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 19, 2026
Sex disparities in receiving evidence-based medications in patients with CKDRui Du, Hannah Wallace, Jeffrey T Ha, et al.
Diabetes Care|June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 26, 2020
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKDFlory T Muanda, Matthew A Weir, Lavanya Bathini, et al.
Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
Pageof 88